Faecal Calprotectin Testing Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Market Overview:

The Faecal Calprotectin Testing Market is expected to grow from USD 201,112 million in 2024 to USD 332,839.48 million by 2032, representing a compound annual growth rate (CAGR) of 6.5%.

This growth is driven by the increasing prevalence of gastrointestinal diseases such as inflammatory bowel disease (IBD) and colorectal cancer, where early detection significantly improves patient outcomes. The growing preference for non-invasive diagnostic methods and the rising demand for personalized healthcare further contribute to market expansion. Technological advancements have enhanced testing methods, making faecal calprotectin testing a preferred diagnostic tool due to its accuracy and efficiency. Additionally, the expanding geriatric population, combined with a stronger focus on early diagnosis and preventive healthcare, is fostering market growth. The integration of faecal calprotectin testing with digital health solutions is enabling improved disease monitoring and management. Increased healthcare investments in emerging markets and partnerships among diagnostic companies are also expected to accelerate market adoption, strengthening overall market dynamics in the years ahead.

Market Drivers:

Non-Invasive Diagnostic Methods:

As healthcare providers and patients prioritize non-invasive diagnostic options, faecal calprotectin testing has gained popularity due to its ability to accurately assess gastrointestinal inflammation without invasive procedures like colonoscopies. For example, Calpro AS offers non-invasive faecal calprotectin test kits that are widely used to assess gastrointestinal inflammation. The preference for non-invasive testing is driven by convenience, reduced risks, and lower patient discomfort, making faecal calprotectin a more appealing option. As more individuals seek reliable, efficient, and minimally disruptive disease detection methods, the adoption of faecal calprotectin testing continues to grow.

Market Challenges:

High Cost of Testing:

A significant challenge in the faecal calprotectin testing market is the high cost associated with these tests, which can limit accessibility, particularly in developing regions. Testing kits, laboratory processing, and necessary follow-up consultations can create a financial burden for both healthcare providers and patients. This is especially problematic in regions with limited healthcare resources or in countries where diagnostic tests are not fully reimbursed by the healthcare system. Although faecal calprotectin testing plays a crucial role in early detection and monitoring of gastrointestinal diseases, its high cost remains a barrier to widespread adoption. Healthcare providers may be hesitant to incorporate these tests into routine practice, which could hinder market growth. Additionally, the need for specialized equipment and trained personnel further increases the expenses, creating challenges for implementation in low-resource settings.

Market Segmentation:

By Assay:

Enzyme-linked Immunosorbent Assay (ELISA)

Enzyme Fluoroimmunoassay

Quantitative Immunochromatography

By Application:

Inflammatory Bowel Disease (IBD)

Colorectal Cancer

Others

By End-Use:

Hospitals and Clinics

Diagnostic Laboratories

Academic and Research Institutes

By Geography:

North America:

U.S.

Canada

Mexico

Europe:

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific:

China

Japan

India

South Korea

Southeast Asia

Rest of Asia Pacific

Latin America:

Brazil

Argentina

Rest of Latin America

Middle East & Africa:

GCC Countries

South Africa

Rest of the Middle East and Africa

Key Players:

Eagle Biosciences, Inc.

Actim

DRG International Inc.

Svar Life Science

ALPCO

Epitope Diagnostics Inc.

OPERON

BÜHLMANN

Hycult Biotech

Diazyme Laboratories